2. Search Result
Search Result
Results for "

gut bacteria

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

9

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0921
    Succinylsulfathiazole
    1 Publications Verification

    Succinylsulphathiazole

    		 Antibiotic Bacterial Dihydrofolate reductase (DHFR) mTOR Infection
    Succinylsulfathiazole (Succinylsulphathiazole) is a long-acting sulfonamide antibiotic with localized gut-specific antibacterial activity and is orally active. Succinylsulfathiazole inhibits bacterial folate synthesis, reduces coliform counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes gut folate-producing bacteria. Succinylsulfathiazole modulates hepatic mTOR signaling, diminishes cecal fermentation, decreases hepatic folate levels and total folate excretion, elevates nitrogen excretion and reduces the fermentability of certain dietary fibers. Succinylsulfathiazole induces folate deficiency and triggers biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice .
    Succinylsulfathiazole
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-P10352A
    Pediocin PA 1 TFA

    		Bacterial Infection
    Pediocin PA-1 TFA is a class IIa bacteriocin that specifically binds to membrane proteins of susceptible Gram-positive bacteria (such as Listeria monocytogenes) to form voltage-independent hydrophilic pores, leading to dissipation of proton motive force, ATP depletion and cell death. Pediocin PA-1 TFA shows no significant activity against intact Gram-negative bacteria, strains carrying immunity genes and obligate anaerobic commensal gut microbiota, and its bactericidal function depends on the integrity of disulfide bonds, with activity lost upon reduction. Pediocin PA-1 TFA can be used not only as a food biopreservative but also for research on listeriosis .
    Pediocin PA 1 TFA
  • HY-157355
    Brain Heart Infusion Broth

    BHI

    		 Biochemical Assay Reagents Bacterial Infection
    Brain Heart Infusion Broth (BHI) is a bacterial culture medium that can be used for microbial culture .
    Brain Heart Infusion Broth
  • HY-N1976
    (+)-(3R,8S)-Falcarindiol
    1 Publications Verification

    (3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol

    		 Infection Cancer
    (+)-(3R,8S)-Falcarindiol ((3R,8S)-Falcarindiol; 3 (R),8 (S),9 (Z)-Falcarindiol) is an orally active polyacetylene anti-mycobacterial agent. (+)-(3R,8S)-Falcarindiol exhibits antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and mycobacteria. Co-administration of (+)-(3R,8S)-Falcarindiol with (3R)-falcarinol alters the composition of gut microbiota, reduces colonic tumor lesions and slows down polyp growth. (+)-(3R,8S)-Falcarindiol can be used in research related to tuberculosis and colorectal cancer .
    (+)-(3R,8S)-Falcarindiol
  • HY-N0299
    Stachyose hydrate
    1 Publications Verification

    		 Endogenous Metabolite Apoptosis Metabolic Disease Inflammation/Immunology
    Stachyose hydrate is an orally active prebiotic that enhances the growth and activity of beneficial bacteria. Stachyose hydrate has hypoglycemic effects and can improve inflammation by regulating gut microbiota. In addition, Stachyose hydrate can induce plant cell apoptosis (Apoptosis). Stachyose hydrate can be used in research on inflammation, gastrointestinal diseases, and agriculture .
    Stachyose hydrate
  • HY-P10352
    Pediocin PA 1

    		Bacterial Infection
    Pediocin PA 1 is a class IIa bacteriocin that specifically binds to membrane proteins of susceptible Gram-positive bacteria (such as Listeria monocytogenes) to form voltage-independent hydrophilic pores, leading to dissipation of proton motive force, ATP depletion and cell death. Pediocin PA 1 shows no significant activity against intact Gram-negative bacteria, strains carrying immunity genes and obligate anaerobic commensal gut microbiota, and its bactericidal function depends on the integrity of disulfide bonds, with activity lost upon reduction. Pediocin PA 1 can be used not only as a food biopreservative but also for research on listeriosis .
    Pediocin PA 1
  • HY-W399297
    Isodeoxycholic acid
    1 Publications Verification

    7α,12α-Dihydroxycholanoic acid

    		 Endogenous Metabolite Metabolic Disease
    Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .
    Isodeoxycholic acid
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-107831
    5-Acetylsalicylic acid
    1 Publications Verification

    		 Drug Derivative Inflammation/Immunology Cancer
    5-Acetylsalicylic acid is the derivate of Aspirin (HY-14654), with anti-inflammatory property. 5-Acetylsalicylic acid is the active metabolite of Sulfasalazine (HY-14655) and its production is regulated by beneficial bacteria in the gut but is confined to the intestinal tract. 5-Acetylsalicylic acid exhibits a mild cytotoxicity effect on B16F10 cells. 5-Acetylsalicylic acid can be used for the study of inflammatory bowel disease (IBD) such as ulcerative colitis (UC) .
    5-Acetylsalicylic acid
  • HY-120536
    HPi1
    1 Publications Verification

    		 Bacterial Infection
    HPi1 is a potent, selective and orally active antimicrobial against Helicobacter pylori with an IC50 of 0.24 μM and an MIC of 0.08-0.16 μg/mL. HPi1 is inactive against other bacteria, including the gut commensals Lactobacillus casei, Lactobacillus reuteri, and Bifidobacterium longum .
    HPi1
  • HY-159669
    Stercobilin hydrochloride (mixture of isomers)

    		HIV Protease Infection Inflammation/Immunology
    Stercobilin hydrochloride (amixture of isomers) is a bile pigment metabolized by gut bacteria, and it's also an HIV protease inhibitor, with a Ki of 4 μM. Stercobilin hydrochloride (a mixture of isomers) can induce pro-inflammatory activity in mouse macrophage RAW264 cells, including the production of TNF-α and IL-1β. Stercobilin hydrochloride (a mixture of isomers) can be used in studies of inflammation and viral infections .
    Stercobilin hydrochloride (mixture of isomers)
  • HY-N0468R
    Rebaudioside D (Standard)

    		Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D (Standard)
  • HY-N8341
    Alphitonin

    		Drug Metabolite Metabolic Disease
    Alphitonin is a flavonoid and is also a metabolic intermediate that is formed during the catabolism of Quercetin (HY-18085) by the human gut bacteria E. ramulus.
    Alphitonin
  • HY-N13267
    (-)-cis-Myrtanol

    		Bacterial Antibiotic Infection
    (-)-cis-Myrtanol is a terpenoid compound derived from Artemisia dracunculus that exhibits effective antibacterial activity against harmful gut bacteria such as Bifidobacterium bifidum .
    (-)-cis-Myrtanol
  • HY-B0921R
    Succinylsulfathiazole (Standard)

    Succinylsulphathiazole (Standard)

    		 Reference Standards Bacterial Antibiotic Dihydrofolate reductase (DHFR) mTOR Infection
    Succinylsulfathiazole (Standard) (Succinylsulphathiazole) is the analytical standard of Succinylsulfathiazole (HY-B0921). This product is intended for research and analytical applications. Succinylsulfathiazole is a long-acting sulfonamide antibiotic with localized gut-specific antibacterial activity and is orally active. Succinylsulfathiazole inhibits bacterial folate synthesis, reduces coliform counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes gut folate-producing bacteria. Succinylsulfathiazole modulates hepatic mTOR signaling, diminishes cecal fermentation, decreases hepatic folate levels and total folate excretion, elevates nitrogen excretion and reduces the fermentability of certain dietary fibers. Succinylsulfathiazole induces folate deficiency and triggers biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice .
    Succinylsulfathiazole (Standard)
  • HY-N16477
    Ciceritol

    		Drug Metabolite Metabolic Disease
    Ciceritol is a dietary fiber component/prebiotic targeting α-galactosidic linkage oligosaccharides. Ciceritol selectively promotes proliferation of beneficial bacteria like Bifidobacteria. Ciceritol is promising for research of gut microbiota-related diseases (e.g., irritable bowel syndrome, metabolic syndrome) .
    Ciceritol
  • HY-107831R
    5-Acetylsalicylic acid (Standard)

    		Reference Standards Others Inflammation/Immunology Cancer
    5-Acetylsalicylic acid (Standard) is the analytical standard of 5-Acetylsalicylic acid (HY-107831). This product is intended for research and analytical applications. 5-Acetylsalicylic acid is the derivate of Aspirin (HY-14654), with anti-inflammatory property. 5-Acetylsalicylic acid is the active metabolite of Sulfasalazine (HY-14655) and its production is regulated by beneficial bacteria in the gut but is confined to the intestinal tract. 5-Acetylsalicylic acid exhibits a mild cytotoxicity effect on B16F10 cells. 5-Acetylsalicylic acid can be used for the study of inflammatory bowel disease (IBD) such as ulcerative colitis (UC) .
    5-Acetylsalicylic acid (Standard)
  • HY-W589560
    TMA-IN-1

    		Endogenous Metabolite Cardiovascular Disease
    TMA-IN-1 (Compound 7) is a highly potent, orally active and selective TMA Lyase inhibitor with an estimated Kd value of 3.2 μM. TMA-IN-1 reduces Trimethylamine oxide (TMAO) levels. TMA-IN-1 can be used for the research of heart failure .
    TMA-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: